The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?

被引:146
作者
Farouk, Samira S. [1 ,2 ]
Rein, Joshua L. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA
[2] Mt Sinai Hosp, Recanati Miller Transplant Inst, New York, NY 10029 USA
关键词
Calcineurin inhibitors; Tacrolimus; Cyclosporine; Drug toxicity; Kidney transplantation; RENAL-TRANSPLANT RECIPIENTS; TACROLIMUS DOSE REQUIREMENTS; CALCIUM-CHANNEL BLOCKERS; TERM CLINICAL-OUTCOMES; NA+/K+-ATPASE ACTIVITY; CYCLOSPORINE-A; KIDNEY-TRANSPLANTATION; P-GLYCOPROTEIN; INTERSTITIAL FIBROSIS; GENETIC POLYMORPHISMS;
D O I
10.1053/j.ackd.2019.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Calcineurin inhibitors (CNIs) are both the savior and Achilles' heel of kidney transplantation. Although CNIs have significantly reduced rates of acute rejection, their numerous toxicities can plague kidney transplant recipients. By 10 years, virtually all allografts will have evidence of CNI nephrotoxicity. CNIs have been strongly associated with hypertension, dyslipidemia, and new onset of diabetes after transplantation significantly contributing to cardiovascular risk in the kidney transplant recipient. Multiple electrolyte derangements including hyperkalemia, hypomagnesemia, hypercalciuria, metabolic acidosis, and hyperuricemia may be challenging to manage for the clinician. Finally, CNI-associated tremor, gingival hyperplasia, and defects in hair growth can have a significant impact on the transplant recipient's quality of life. In this review, the authors briefly discuss the pharmacokinetics of CNI and discuss the numerous clinically relevant toxicities of commonly used CNIs, cyclosporine and tacrolimus. (C) 2019 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:56 / 66
页数:11
相关论文
共 159 条
[1]  
ADU D, 1983, LANCET, V2, P370
[2]   Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids [J].
Akman, B. ;
Uyar, M. ;
Afsar, B. ;
Sezer, S. ;
Ozdemir, F. N. ;
Haberal, M. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (01) :135-137
[3]   REDUCED ERYTHROCYTE AND LEUKOCYTE MAGNESIUM IS ASSOCIATED WITH CYCLOSPORINE TREATMENT AND HYPERTENSION IN RENAL-TRANSPLANT PATIENTS [J].
ALKHURSANY, I ;
THOMAS, TH ;
HARRISON, K ;
WILKINSON, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (03) :251-255
[4]  
ANDOH TF, 1994, TRANSPLANTATION, V57, P483
[5]  
Anghel Daniela, 2013, Maedica (Bucur), V8, P170
[6]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[7]  
[Anonymous], PEDIAT TRANSPL
[8]   Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014) [J].
Awan, Ahmed A. ;
Niu, Jingbo ;
Pan, Jenny S. ;
Erickson, Kevin F. ;
Mandayam, Sreedhar ;
Winkelmayer, Wolfgang C. ;
Navaneethan, Sankar D. ;
Ramanathan, Venkat .
AMERICAN JOURNAL OF NEPHROLOGY, 2018, 48 (06) :472-481
[9]   Fludrocortisone as a new tool for managing tubulopathy after pediatric renal transplantation: a series of cases [J].
Bacchetta, Justine ;
Basmaison, Odile ;
Leclerc, Anne-Laure ;
Bertholet-Thomas, Aurelia ;
Cochat, Pierre ;
Ranchin, Bruno .
PEDIATRIC NEPHROLOGY, 2014, 29 (10) :2061-2064
[10]   Dyslipidemia Following Kidney Transplantation: Diagnosis and Treatment [J].
Badiou, Stephanie ;
Cristol, Jean-Paul ;
Mourad, Georges .
CURRENT DIABETES REPORTS, 2009, 9 (04) :305-311